鲁抗医药：控股子公司获得美索巴莫注射液补充申请批准通知书

Core Viewpoint - The announcement by LuKang Pharmaceutical indicates that its subsidiary, Shandong LuKang Pharmaceutical Group Sait Company, has received approval from the National Medical Products Administration for the marketing authorization of Mesobam Injection, which is expected to positively impact the company's future operations [1] Group 1: Company Developments - LuKang Pharmaceutical's subsidiary has been granted the marketing authorization holder status for Mesobam Injection, previously held by Beijing Minkan Baicao Pharmaceutical Technology Co., Ltd [1] - The approval aligns with the regulatory requirements for drug registration, allowing the company to optimize its product structure and maintain stable production capacity [1] - The drug is clinically used for treating joint and muscle sprains, lumbar muscle strain, and can also be used for the treatment of spondylitis and rheumatoid arthritis [1] Group 2: Market Context - There are currently 26 companies with 30 production licenses for Mesobam Injection in the domestic market, indicating a competitive landscape [1] - The transition of marketing authorization to Sait Company is expected to help meet market demand effectively [1]